Copyright
©The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Feb 27, 2026; 18(2): 114346
Published online Feb 27, 2026. doi: 10.4254/wjh.v18.i2.114346
Published online Feb 27, 2026. doi: 10.4254/wjh.v18.i2.114346
Effects of tenofovir amibufenamide and entecavir on estimated glomerular filtration rate in treatment-naïve patients with chronic hepatitis B
Shi-Peng Ma, Liang Wang, Yu-Liang Zhang, Xin Wan, Qian Liu, Yu-Lun Tang, Lajpat-Rai Malhi, Shan-Fei Ge, Department of Infectious Diseases, The First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China
Shi-Peng Ma, Department of Nephrology, 3201 Hospital, Hanzhong 723000, Shaanxi Province, China
Co-first authors: Shi-Peng Ma and Liang Wang.
Author contributions: Ma SP contributed to data organization and research design; Ma SP, Wang L, and Zhang YL contributed to manuscript writing; Ma SP, Wang L, Zhang YL, Wan X, Liu Q, and Tang YL contributed to data collection; Malhi LR contributed to manuscript review; Ge SF contributed to research design guidance, writing guidance, and final manuscript revision. Ma SP and Wang L contributed equally to this manuscript and are co-first authors.
Supported by Chinese Foundation for Hepatitis Prevention and Control Muxin Research Fund of Chronic Hepatitis B, No. MX202418.
Institutional review board statement: This study was approved by the Ethics Committee of the First Affiliated Hospital of Nanchang University [Approval No. (2021) Medical Research Ethics Review (8-016)].
Informed consent statement: As this study was conducted retrospectively, the requirement for written informed consent was waived.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement: All data included in this study are available upon request from the corresponding author.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shan-Fei Ge, Department of Infectious Diseases, The First Affiliated Hospital of Nanchang University, No. 17 Yongwai Zheng Street, Donghu District, Nanchang 330006, Jiangxi Province, China. geshanfei2010@163.com
Received: September 19, 2025
Revised: November 1, 2025
Accepted: December 11, 2025
Published online: February 27, 2026
Processing time: 147 Days and 8.5 Hours
Revised: November 1, 2025
Accepted: December 11, 2025
Published online: February 27, 2026
Processing time: 147 Days and 8.5 Hours
Core Tip
Core Tip: This study provides the comparison of renal safety between tenofovir amibufenamide (TMF) and entecavir (ETV) in treatment-naive chronic hepatitis B patients. After propensity score matching, TMF showed significantly less decline in estimated glomerular filtration rate over 48 weeks than ETV. Baseline estimated glomerular filtration rate and triglyceride levels independently predicted abnormal renal function, highlighting TMF’s potential renal safety advantage over ETV and offering clinicians important insights for individualized antiviral therapy.